Clinical trial
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients…
NCT00098475 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00098475 |
|---|---|
| Title | Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma |
| Official title | A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide |
| Enrollment | 452 |
| Start date | Nov 3, 2004 |
| Primary completion | Nov 30, 2008 |
| Completion | Oct 23, 2026 |
| First posted | Dec 8, 2004 |
| Last update posted | Nov 28, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: